Скачать или смотреть Cobolimab Unveiling TIM-3’s Role in Cancer Immunotherapy

https://www.assaygenie.com/anti-tim3-...

Key takeaways:

Cobolimab is a monoclonal antibody that targets TIM-3, an immune checkpoint protein often exploited by tumors to evade the immune system. Blocking TIM-3 with Cobolimab reactivates T-cells, bolstering the body’s natural anti-tumor response.
The mechanism of action involves preventing TIM-3 from interacting with ligands like Galectin-9, thus stopping the suppression of T-cells and enabling sustained anti-tumor activity. This approach also improves the function of other immune cells like dendritic cells.
Cobolimab is being explored as a potential treatment for a variety of cancers, including melanoma, lung cancer, colorectal cancer, and lymphoma. It shows particular promise in combination therapies alongside PD-1/PD-L1 inhibitors, where it can help overcome resistance and enhance overall effectiveness.
Assay Genie offers a Cobolimab biosimilar specifically for research purposes, allowing scientists to further investigate the drug's mechanisms and applications in a cost-effective manner. This biosimilar is not for clinical or therapeutic use.

Important Quotes:

"By inhibiting TIM-3, Cobolimab reactivates T-cells, boosting the immune system’s ability to identify and destroy cancer cells."
"This combination approach provides a synergistic effect, boosting overall immune-mediated tumor destruction."
"Tumors often exploit multiple immune checkpoint pathways, including TIM-3, to evade immune detection."
"By combining Cobolimab with PD-1/PD-L1 therapies, researchers aim to overcome this resistance by simultaneously targeting complementary immune-suppressive mechanisms, leading to a more robust anti-tumor response."